In the past one month or so, many companies having exposure to the US markets, such as Aurobindo Pharma, Lupin, Cipla, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, and Biocon, were in the spotlight over FDA issues. Lupin, Glenmark, and Torrent Pharma have received Warning Letters for their facilities recently. With companies like Cadila Healthcare, IPCA, and Dr Reddy's already struggling to resolve their FDA issues, the list has only grown longer. Analysts at Jefferies, not long back, had said that US FDA focus on Indian facilities has increased over the past 12 months, with more than 30 per cent of ex-US inspections being for Indian facilities, as against 20 per cent earlier.